Sugi Predict

Sugi Predict / Compounds / SCHEMBL1401719

SCHEMBL1401719

SCHEMBL1401719

COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OC[C@@H]1CCCN1C(N)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 12/20 0.63
▸ RET P07949 3/20 0.63
▸ PDGFRB P09619 2/20 0.63
▸ PLK4 O00444 1/20 0.63
▸ GAK O14976 1/20 0.63
▸ EPHB6 O15197 1/20 0.63
▸ RIPK2 O43353 1/20 0.63
▸ ERN1 O75460 1/20 0.63
▸ STK10 O94804 1/20 0.63
▸ MAP4K4 O95819 1/20 0.63
▸ CHEK2 O96017 1/20 0.63
▸ ABL1 P00519 1/20 0.63
▸ EGFR P00533 1/20 0.63
▸ ERBB2 P04626 1/20 0.63
▸ LCK P06239 1/20 0.63
▸ FYN P06241 1/20 0.63
▸ CSF1R P07333 1/20 0.63
▸ YES1 P07947 1/20 0.63
▸ LYN P07948 1/20 0.63
▸ MET P08581 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3920841 0.93 KDR (0.64) KDRRETPDGFRBPLK4GAK
SCHEMBL1401633 0.93 KDR (0.64) KDRRETPDGFRBPLK4GAK
SCHEMBL3917975 0.93 KDR (0.64) KDRRETPDGFRBPLK4GAK
SCHEMBL1401632 0.93 KDR (0.64) KDRRETPDGFRBPLK4GAK
SCHEMBL1401680 0.93 KDR (0.64) KDRRETPDGFRBPLK4GAK
SCHEMBL1401643 0.91 KDR (0.61) KDRRETPDGFRBPLK4GAK
SCHEMBL1401686 0.91 KDR (0.61) KDRRETPDGFRBPLK4GAK
SCHEMBL1401707 0.90 KDR (0.60) KDRRETPDGFRBPLK4GAK
SCHEMBL1401733 0.90 KDR (0.60) KDRRETPDGFRBPLK4GAK
SCHEMBL1401684 0.86 KDR (0.64) KDRRETPDGFRBPLK4GAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 — — US claimed
EP-2292615-A1 Quinazoline compounds AstraZeneca AB (SE) 2011-03-09 — — EP claimed
US-20080027069-A1 Quinazoline compounds ASTRAZENECA AB 2008-01-31 — — US claimed
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents ASTRAZENECA AB (SE) 2005-04-21 — — US claimed
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 — — US disclosed
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 — — US disclosed
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 — — US disclosed
EP-2292615-A1 Quinazoline compounds AstraZeneca AB (SE) 2011-03-09 — — EP disclosed
EP-2292615-A1 Quinazoline compounds AstraZeneca AB (SE) 2011-03-09 — — EP disclosed
US-20100029673-A1 THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE ASTRAZENECA AB (SE) 2010-02-04 — — US disclosed
US-20090156821-A1 Quinazoline compounds ASTRAZENECA AB 2009-06-18 — — US disclosed
US-20090156821-A1 Quinazoline compounds ASTRAZENECA AB 2009-06-18 — — US disclosed
US-20080027069-A1 Quinazoline compounds ASTRAZENECA AB 2008-01-31 — — US disclosed
US-7268230-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2007-09-11 — — US disclosed
US-7268230-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2007-09-11 — — US disclosed
US-7268230-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2007-09-11 — — US disclosed
US-20060223815-A1 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use ASTRAZENECA AB (SE) 2006-10-05 — — US disclosed
EP-1620104-A1 THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE Astrazeneca AB (SE) 2006-02-01 — — EP disclosed
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents ASTRAZENECA AB (SE) 2005-04-21 — — US disclosed
WO-2004098604-A1 THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE ASTRAZENECA AB (SE) 2004-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223815-A1 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use SRC, TEK, FLT4 KDR 5/4885RET 145/4885PDGFRB 18/4885
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents VEGFA, FLT4, FLT1 KDR 4/4885RET 3578/4885PDGFRB 1557/4885
US-20100029673-A1 THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE SRC, CHUK, CTTN KDR 10/4885RET 209/4885PDGFRB 24/4885
US-20090156821-A1 Quinazoline compounds VEGFA, FLT4, FLT1 KDR 5/4885RET 2725/4885PDGFRB 1748/4885
US-20080027069-A1 Quinazoline compounds VEGFA, FLT4, FLT1 KDR 5/4885RET 2725/4885PDGFRB 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.